Skip to main content

Table 1 Characteristics of the study patients

From: Prognostic role of multiparameter MRI and radiomics in progression of advanced unresectable hepatocellular carcinoma following combined transcatheter arterial chemoembolization and lenvatinib therapy

Clinical characteristic

Patient (n = 61)

Age

 

≥ 65

25

< 65

36

Gender

 

Male

55

Female

6

Weight

 

≥ 60 kg

23

< 60 kg

38

BCLC

 

A

3

B

19

C

39

Child–Pugh

 

A

55

B

6

Tumor numbers

 

1

12

≥ 2

39

Tumor size (cm)

 

HBV

 

Positivity

57

Negative

4

AFP (ng/ml)

 

≥ 400

32

< 400

29

GGT (U/L)

 

≥ 60

45

< 60

16

ALP (U/L)

 

≥ 125

26

< 125

35

AST (U/L)

 

≥ 40

46

< 40

15

ALT (U/L)

 

≥ 50

34

< 50

27

ALB (g/L)

39.1 ± 5.2

TBIL (µmol/L)

18.9 ± 15.0

PT (s)

12.4 ± 1.2

NLR

3.0 ± 1.9

LMR

4.0 ± 2.1

PLR

154.6 ± 76.7

PNI

47.8 ± 7.3

SII

671.1 ± 565.6

  1. AFP, alpha-fetoprotein; AST, aspartate aminotransferase; ALP, alkaline phosphatase; ALT, Alanine aminotransferase. ALB, Albumin; BCLC, Barcelona Clinic Liver Cancer; HBV, hepatitis B virus; Child–Pugh; GGT, γ-glutamyl transpeptidase;LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PNI, prognostic nutritional index; PT, Prothrombin time; SII, systemic immune-inflammation index; TBIL, total bilirubin